zidovudine has been researched along with apricitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brenner, BG; Lalonde, R; Micheli, V; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Brenner, BG; Cox, S; Moisi, D; Oliveira, M; Spira, B; Wainberg, MA | 1 |
2 other study(ies) available for zidovudine and apricitabine
| Article | Year |
|---|---|
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Topics: Adenine; Amino Acid Sequence; Deoxycytidine; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Mutation; Organophosphonates; Phenotype; Ribonuclease H; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Tenofovir; Zidovudine | 2007 |
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.
Topics: Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2009 |